[breadcrumb_custom]

Silence Therapeutics Plc ADR (NASDAQ:SLN) -1.72% Down Over Last Week, What Happens Next?

In last trading session, Silence Therapeutics Plc ADR (NASDAQ:SLN) saw 1.85 million shares changing hands with its beta currently measuring 1.40. Company’s recent per share price level of $21.20 trading at $0.16 or 0.76% at ring of the bell on the day assigns it a market valuation of $819.80M. That closing price of SLN’s stock is at a discount of -14.76% from its 52-week high price of $24.33 and is indicating a premium of 78.54% from its 52-week low price of $4.55. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.2 million shares which gives us an average trading volume of 144.05K if we extend that period to 3-months.

Silence Therapeutics Plc ADR (NASDAQ:SLN) trade information

Upright in the green during last session for gaining 0.76%, in the last five days SLN remained trading in the red while hitting it’s week-highest on Friday, 02/02/24 when the stock touched $21.20 price level, adding 7.42% to its value on the day. Silence Therapeutics Plc ADR’s shares saw a change of 22.05% in year-to-date performance and have moved -1.72% in past 5-day. Silence Therapeutics Plc ADR (NASDAQ:SLN) showed a performance of 20.52% in past 30-days. Number of shares sold short was 0.13 million shares which calculate 1.26 days to cover the short interests.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Silence Therapeutics Plc ADR (SLN) estimates and forecasts

Statistics highlight that Silence Therapeutics Plc ADR is scoring comparatively higher than the scores of other players of the relevant industry. The company added 280.61% of value to its shares in past 6 months, showing an annual growth rate of 14.10% while that of industry is 11.30. Apart from that, the company came raising its revenue forecast for fiscal year 2024.

SLN Dividends

Silence Therapeutics Plc ADR is more likely to be releasing its next quarterly report in March and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Silence Therapeutics Plc ADR (NASDAQ:SLN)’s Major holders

Insiders are in possession of 23.60% of company’s total shares while institution are holding 50.39 percent of that, with stock having share float percentage of 65.96%. Investors also watch the number of corporate investors in a company very closely, which is 50.39% institutions for Silence Therapeutics Plc ADR that are currently holding shares of the company. Lombard Odier Asset Management (USA) Corp is the top institutional holder at SLN for having 4.12 million shares of worth $22.66 million. And as of Jun 29, 2023, it was holding 13.77% of the company’s outstanding shares.

The second largest institutional holder is Lombard Odier Asset Management (Europe) Ltd, which was holding about 3.42 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 11.41% of outstanding shares, having a total worth of $18.78 million.

On Key

Related Posts